Table 4.
n (%) | Tiotropium Respimat®5 μg QD(n = 98) | Tiotropium Respimat®2.5 μg BID(n = 98) |
---|---|---|
Any adverse event | 18 (18.4) | 19 (19.4) |
Nasopharyngitis | 4 (4.1) | 4 (4.1) |
Headache | 3 (3.1) | 2 (2.0) |
Dysphonia | 1 (1.0) | 2 (2.0) |
Rhinitis | 1 (1.0) | 2 (2.0) |
Asthma worsening | 2 (2.0) | 0 |
Contusion | 2 (2.0) | 0 |
Cough | 0 | 2 (2.0) |
Dry mouth | 0 | 2 (2.0) |
Rash | 1 (1.0) | 1 (1.0) |
Urticaria | 1 (1.0) | 1 (1.0) |
Investigator-defined drug-related adverse events | 1 (1.0) | 2 (2.0) |
Adverse events leading to discontinuation | 0 | 1 (1.0) |
Serious adverse events | 0 | 1 (1.0) |
Treated set.
Frequency of adverse events that occurred in more than one patient in any treatment group, sorted by preferred term and system organ class.
BID, twice daily; QD, once daily.